Pharmaceuticals, Biotechnology and Life Sciences
The US Food and Drug Administration (FDA) has approved Novartis’s Kisqali (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
Novartis has reported new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx (secukinumab) rapidly regain clear or almost clear skin (Psoriasis Area Severity Index, PASI 90 to 100) following relapse during a treatment pause. Also showed no anti-secukinumab antibodies were observed during retreatment.
Novartis’s division Sandoz has reported that Phase 3 confirmatory efficacy, safety and immunogenicity study met its primary endpoint demonstrating biosimilar adalimumab GP2017 has equivalent efficacy to the reference medicine, Humira.
Novartis is making progress in its bid to catch rivals developing drugs that harness the immune system to fight cancer, one of its top research scientists and latest recruit from Harvard University told Reuters in an interview
Novartis could get first targeted treatment for patients with BRAF non-small cell lung cancer if European Medicines Agency (EMA) approves Tafinlar+Mikinist combination.
US Food and Drug Administration (FDA) has accepted Novartis’s supplemental New Drug Application (sNDA) for filing, and granted Priority Review for the expanded use of Zykadia (ceritinib) as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
Several leaders of some of the largest pharmaceutical companies have met on Tuesday with the newly elected US president, Donald Trump to discuss industry related topics, agreeing that the talks were positive.
U.S. President Donald Trump, who has accused drugmakers of “getting away with murder” on prices, will meet executives from the pharmaceutical industry at the White House on Tuesday.
European Commission has approved Novartis’s Votubia (everolimus) dispersible tablets as an adjunctive treatment for patients aged two years and older whose…
Alcon and a division of Novartis have launched AcrySof IQ PanOptix Toric presbyopia- and astigmatism-correcting intraocular lens (IOL) for patients with pre-existing corneal astigmatism undergoing cataract surgery.